Skip to search boxSkip to navigationSkip to main content

Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor

  • F. M. Kong
    ,
  • M. S. Anscher
    ,
  • T. Murase
    ,
  • B. D. Abbott
    ,
  • J. D. Iglehart
    ,
  • R. L. Jirtle(corresponding author)
*Corresponding author for this work
  • Duke University
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Objective: The authors determined whether untreated breast cancer patients have elevated plasma levels of transforming growth factor-β1 (TGF-β1). Summary Background Data: Increased plasma TGF-β1 levels recently were found after chemotherapy in patients with advanced breast cancer. However, it currently is unknown whether this elevation in plasma TGF-β1 is caused by chemotherapy-induced normal tissue damage or whether it results from the presence of the tumor. Methods: An enzyme-linked immunosorbent assay was used to measure plasma TGF-β1 levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. Patients were grouped by postoperative tumor status: 1) negative lymph nodes (group 1); 2) positive lymph nodes (group 2); and 3) overt residual disease (group 3). The site of TGF-β1 production in the tumors was localized by immunohistochemistry and in situ hybridization. Results: Plasma TGF-β1 levels were elevated preoperatively in 81% of the patients; TGF-β2 and TGF-β3 were undetectable. The preoperative TGF-β1 levels in the three patient groups were similar; however, the postoperative plasma TGF-β1 levels differed by disease status. The mean plasma TGF-β1 level in group 1 (n = 12) normalized after surgery (19.3 ± 3.2 vs. 5.5 ± 1.0 ng/mL, p < 0.081). In contrast, the mean plasma TGF-β1 levels remained above normal in both group 2 (n = 9) and group 3 (n = 5) after surgery. Transforming growth factor-β1 expression was found to be preferentially increased in the tumor stroma. Conclusions: Breast tumors result in increased plasma TGF-β1 levels in 81% of patients. After surgical removal of the primary tumor, the plasma TGF-β1 level normalizes in the majority of patients; persistently elevated levels correlate with the presence of lymph node metastases or overt residual tumor. These findings suggest that the usefulness of TGF-β1 as a potential plasma marker for breast tumors deserves further study.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 155-162 (8 pages)

Journal (Volume, Issue Number)

Annals of surgery (Volume 222, Issue 2)

Publication milestones

  • Published - 1995

Publication status

Published - 1995

ISSN

0003-4932

Publication IDs

  • Scopus: 0029133133
  • PubMed: 7543740

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
48
Citation count
187